Cargando…
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
BACKGROUND: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels with subsequent pCR, few have studi...
Autores principales: | Eustace, A. J., Madden, S. F., Fay, J., Collins, D. M., Kay, E. W., Sheehan, K. M., Furney, S., Moran, B., Fagan, A., Morris, P. G., Teiserskiene, A., Hill, A. D., Grogan, L., Walshe, J. M., Breathnach, O., Power, C., Duke, D., Egan, K., Gallagher, W. M., O’Donovan, N., Crown, J., Toomey, S., Hennessy, B. T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197702/ https://www.ncbi.nlm.nih.gov/pubmed/33983492 http://dx.doi.org/10.1007/s10549-021-06244-1 |
Ejemplares similares
-
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017) -
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
por: Gaynor, Nicola, et al.
Publicado: (2023) -
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023) -
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021) -
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
por: MAHGOUB, T., et al.
Publicado: (2015)